A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat

PHASE3CompletedINTERVENTIONAL
Enrollment

449

Participants

Timeline

Start Date

June 19, 2015

Primary Completion Date

August 24, 2016

Study Completion Date

August 24, 2016

Conditions
Smallpox
Interventions
DRUG

tecovirimat

Study is based on Animal Regulatory Rule

OTHER

Placebo

Does not apply

Trial Locations (11)

29407

Medical Research South, Charleston

36608

Coastal Clinical Research, Inc., Mobile

63141

Sundance Clinical Research LLC, St Louis

64114

Center for Pharmaceutical Research, Kansas City

66219

Johnson County Clinical Trials, Lenexa

67114

Heartland Research Associates, LLC, Newton

68134

Meridien Clinical Research, Omaha

76135

Benchmark Research, Fort Worth

78705

Benchmark Research, Austin

92117

Paradigm Research, San Diego

96001

Paradigm Research, Redding

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

SIGA Technologies

INDUSTRY

NCT02474589 - A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat | Biotech Hunter | Biotech Hunter